Skip to main content
. 2022 Oct 21;76(5):850–860. doi: 10.1093/cid/ciac830

Figure 3.

Figure 3.

Comprehensive assessment of 8 subjects with genomically supported persistent RNA detection in the context of MA COVID-19 cases. A, Global phylogeny annotated with persistent RNA detection. B, Individual timelines of subjects with genomically supported persistent RNA detection annotated with nucleic acid amplification test results, Ct values (when available), COVID-19 symptomatology, and SARS-CoV-2 PANGO lineages (when available). Abbreviations: ALL, acute lymphoblastic leukemia; ALS, amyotrophic lateral sclerosis; BMT, bone marrow transplant; CAD, coronary artery disease; CHF, congestive heart failure; COVID, coronavirus disease; COVID-19, coronavirus disease 2019; Ct, cycle threshold; DDKT, deceased donor kidney transplant; DLBCL, diffuse large B-cell lymphoma; ESRD, end-stage renal disease; F, female; GVHD, graft versus host disease; IS, immunosuppressed; M, male; MA, Massachusetts; NAAT, nucleic acid amplification test; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.